Synonyms: ((2R,3S,4R,5R)-3,4-Dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate; (oh)4Cyd lester; 4-N-HO-Cyd ester; BHC ester; EIDD 1931 5'-isopropylester; EIDD 1931 prodrug; EIDD 2801; EIDD-1931 5'-isopropylester; EIDD-1931 prodrug; EIDD1931 5'-isopropylester; EIDD1931 prodrug; EIDD2801; N4-Hydroxycytidine 5'-isopropylester; N4-OHcyd ester; N4OHcyd ester; NHC ester; beta-D-N4-Hydroxycytidine 5'-isopropylester
Molecular Formula: C13H19N3O7
Molecular Weight: 329.31
Linear Structural Formula: C13H19N3O7
Purity: >=98% (HPLC)
Storage: -20C
Biochem Physiol Actions: EIDD-2801 is an orally active, 5'-isopropylester prodrug form of the antiviral ribonucleoside analog N4-hydroxycytidine (NHC, EIDD-1931) with known anti-viral activity against SARS-CoV, SARS-CoV-2, RSV, influenza A & B (IAV & IBV), HCV, pestivirus, bovine viral diarrhoea virus (BVDV), Ebola (EBOV), Chikungunya (CHIKV), venezuelan equine encephalitis (VEEV). EIDD-2801 is efficiently hydrolyzed to NHC in vivo, being more orally bioavailable than NHC in nonhuman primates and ferrets, while maintaining similar oral bioavailability as NHC in mice. EIDD-2801 displays in vivo efficacy against pandemic and seasonal IAV strains in ferrets (lowest ED = 2.3 and 7 mg/kg b.i.d. p.o., respectively).